{"protocolSection": {"identificationModule": {"nctId": "NCT00765947", "orgStudyIdInfo": {"id": "CSPP100A2360"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension", "officialTitle": "A Twenty-four Week, Open-label, Non-comparative, Multi-center Study to Assess the Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension."}, "statusModule": {"statusVerifiedDate": "2020-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-09", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2009-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-10-02", "studyFirstSubmitQcDate": "2008-10-02", "studyFirstPostDateStruct": {"date": "2008-10-03", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-12-13", "resultsFirstSubmitQcDate": "2010-12-13", "resultsFirstPostDateStruct": {"date": "2011-01-11", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2020-07-23", "lastUpdatePostDateStruct": {"date": "2020-08-06", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study will assess the efficacy of an aliskiren based treatment regimen in reaching blood pressure (BP) target in patients with mild to moderate hypertension. (defined as mean sitting Systolic Blood Pressure \\[msSBP\\] \u2265 140 mmHg and \\< 180 mmHg and/or mean sitting Diastolic Blood Pressure \\[msDBP\\] \u2265 90 and \\<110 mmHg)."}, "conditionsModule": {"conditions": ["Essential Hypertension ( Mild to Moderate)"], "keywords": ["Essential Hypertension ( mild to moderate)"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 256, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Aliskiren-based regimen", "type": "EXPERIMENTAL", "description": "All pts starting on aliskiren 150 mg (uptitrated to aliskiren 300 mg), followed by the addition of HCTZ 12.5 mg (uptitrated to 25 mg) and amlodipine 5 mg (uptitrated to 10 mg), as necessary to achieve the Blood Pressure goal.", "interventionNames": ["Drug: Aliskiren", "Drug: Hydrochlorothiazide", "Drug: Amlodipine"]}], "interventions": [{"type": "DRUG", "name": "Aliskiren", "description": "Aliskiren 150 or 300 mg", "armGroupLabels": ["Aliskiren-based regimen"]}, {"type": "DRUG", "name": "Hydrochlorothiazide", "description": "Hydrochlorothiazide 12.5 or 25 mg", "armGroupLabels": ["Aliskiren-based regimen"]}, {"type": "DRUG", "name": "Amlodipine", "description": "Amlodipine 5 or 10 mg", "armGroupLabels": ["Aliskiren-based regimen"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percentage of Participants (Defined as Estimated Cumulative Control Rate) Reaching Blood Pressure Target in a Stepped Care, Aliskiren-based Regimen", "description": "For non diabetic patients the Blood Pressure target is defined as mean sitting Systolic Blood Pressure \\[msSBP\\] \\< 140 mmHg and mean sitting Diastolic Blood Pressure \\[msDBP\\] \\< 90 mmHg and for diabetic patients the Blood Pressure target is mean sitting Systolic Blood Pressure \\[msSBP\\] \\< 130 mmHg and mean sitting Diastolic Blood Pressure \\[msDBP\\] \\< 80 mmHg.", "timeFrame": "24 weeks"}], "secondaryOutcomes": [{"measure": "Percentage of Patients (Defined as Estimated Cumulative Control Rate) Reaching Blood Pressure Target in a Stepped-care, Aliskiren-based Regimen by Patient Subgroups of Mild and Moderate Hypertensive Patients, and Non-diabetic and Diabetic Patients.", "description": "For non diabetic patients the Blood Pressure target is defined as mean sitting Systolic Blood Pressure \\[msSBP\\] \\< 140 mmHg and mean sitting Diastolic Blood Pressure \\[msDBP\\] \\< 90 mmHg and for diabetic patients the Blood Pressure target is mean sitting Systolic Blood Pressure \\[msSBP\\] \\< 130 mmHg and mean sitting Diastolic Blood Pressure \\[msDBP\\] \\< 80 mmHg.", "timeFrame": "24 weeks"}, {"measure": "Changes From Baseline to Week 24 in Mean Sitting Systolic Blood Pressure [msSBP] and Mean Sitting Diastolic Blood Pressure [msDBP]", "timeFrame": "Baseline and Week 24"}, {"measure": "Percent of Responders for Mean Sitting Systolic Blood Pressure [msSBP] and for Mean Sitting Diastolic Blood Pressure [msDBP]", "description": "Response for mean sitting Systolic Blood Pressure \\[msSBP\\] is defined as a reduction of \u2265 20 mmHg from baseline or mean sitting Systolic Blood Pressure \\[msSBP\\] \\< 140 mmHg (non diabetics) or \\< 130 mmHg (diabetics). Response for mean sitting Diastolic Blood Pressure \\[msDBP\\] is defined as a reduction of \u226510 mmHg from baseline or mean sitting Diastolic Blood Pressure \\[msDBP\\] \\< 90 mmHg (non diabetic) or \\< 80 mmHg (diabetics).", "timeFrame": "24 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Outpatients \u2265 18 years of age\n* Patients with a diagnosis of mild to moderate hypertension at Visit 1\n* All patients must have a msSBP \u2265 140 mmHg and \\< 180 mmHg and/or msDBP \u2265 90 mmHg and \\< 110 mmHg mmHg at Visit 3\n\nExclusion Criteria:\n\n* Severe hypertension defined as msSBP \u2265 180 mmHg and/or msDBP \u2265 110 mmHg\n* Secondary form of hypertension\n* Current diagnosis of heart failure (NYHA Class II-IV)\n* Current angina pectoris requiring pharmacological therapy (other than stable doses of oral or topical nitrates)\n* Second or third degree heart block without a pacemaker\n* Concurrent potentially life threatening arrhythmia or symptomatic arrhythmia, atrial fibrillation or atrial flutter, during the 12 months prior to Visit 1\n\nOther protocol-defined inclusion/exclusion criteria may apply.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Investigative Site", "city": "Paris", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "Investigative Site", "city": "Budapest", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Investigative Site", "city": "Bucharest", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Investigative Site", "city": "Bratislava", "country": "Slovakia", "geoPoint": {"lat": 48.14816, "lon": 17.10674}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Aliskiren-based Regimen", "description": "Patients initiated treatment with aliskiren 150 mg (up-titrated to aliskiren 300 mg), followed by the addition of HCTZ 12.5 mg (up-titrated to 25 mg) and amlodipine 5 mg (up-titrated to 10 mg), as necessary to achieve the Blood Pressure goal."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "256"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "232"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "24"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Aliskiren-based Regimen", "description": "Patients initiated treatment with aliskiren 150 mg (up-titrated to aliskiren 300 mg), followed by the addition of HCTZ 12.5 mg (up-titrated to 25 mg) and amlodipine 5 mg (up-titrated to 10 mg), as necessary to achieve the Blood Pressure goal."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "256"}]}], "measures": [{"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "< 65 yrs", "categories": [{"measurements": [{"groupId": "BG000", "value": "203"}]}]}, {"title": "\u2265 65 yrs", "categories": [{"measurements": [{"groupId": "BG000", "value": "53"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "113"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "143"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percentage of Participants (Defined as Estimated Cumulative Control Rate) Reaching Blood Pressure Target in a Stepped Care, Aliskiren-based Regimen", "description": "For non diabetic patients the Blood Pressure target is defined as mean sitting Systolic Blood Pressure \\[msSBP\\] \\< 140 mmHg and mean sitting Diastolic Blood Pressure \\[msDBP\\] \\< 90 mmHg and for diabetic patients the Blood Pressure target is mean sitting Systolic Blood Pressure \\[msSBP\\] \\< 130 mmHg and mean sitting Diastolic Blood Pressure \\[msDBP\\] \\< 80 mmHg.", "populationDescription": "Full analysis set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "24 weeks", "groups": [{"id": "OG000", "title": "Aliskiren-based Regimen", "description": "Patients initiated treatment with aliskiren 150 mg (up-titrated to aliskiren 300 mg), followed by the addition of HCTZ 12.5 mg (up-titrated to 25 mg) and amlodipine 5 mg (up-titrated to 10 mg), as necessary to achieve the Blood Pressure goal."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "256"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "86.12"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients (Defined as Estimated Cumulative Control Rate) Reaching Blood Pressure Target in a Stepped-care, Aliskiren-based Regimen by Patient Subgroups of Mild and Moderate Hypertensive Patients, and Non-diabetic and Diabetic Patients.", "description": "For non diabetic patients the Blood Pressure target is defined as mean sitting Systolic Blood Pressure \\[msSBP\\] \\< 140 mmHg and mean sitting Diastolic Blood Pressure \\[msDBP\\] \\< 90 mmHg and for diabetic patients the Blood Pressure target is mean sitting Systolic Blood Pressure \\[msSBP\\] \\< 130 mmHg and mean sitting Diastolic Blood Pressure \\[msDBP\\] \\< 80 mmHg.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "24 weeks", "groups": [{"id": "OG000", "title": "Aliskiren-based Regimen", "description": "Patients initiated treatment with aliskiren 150 mg (up-titrated to aliskiren 300 mg), followed by the addition of HCTZ 12.5 mg (up-titrated to 25 mg) and amlodipine 5 mg (up-titrated to 10 mg), as necessary to achieve the Blood Pressure goal."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "256"}]}], "classes": [{"title": "Mild Hypertensive", "categories": [{"measurements": [{"groupId": "OG000", "value": "91.48"}]}]}, {"title": "Moderate Hypertensive", "categories": [{"measurements": [{"groupId": "OG000", "value": "79.24"}]}]}, {"title": "Non-diabetic", "categories": [{"measurements": [{"groupId": "OG000", "value": "92.74"}]}]}, {"title": "Diabetic", "categories": [{"measurements": [{"groupId": "OG000", "value": "72.58"}]}]}]}, {"type": "SECONDARY", "title": "Changes From Baseline to Week 24 in Mean Sitting Systolic Blood Pressure [msSBP] and Mean Sitting Diastolic Blood Pressure [msDBP]", "populationDescription": "Full analysis set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Aliskiren-based Regimen", "description": "Patients initiated treatment with aliskiren 150 mg (up-titrated to aliskiren 300 mg), followed by the addition of HCTZ 12.5 mg (up-titrated to 25 mg) and amlodipine 5 mg (up-titrated to 10 mg), as necessary to achieve the Blood Pressure goal."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "251"}]}], "classes": [{"title": "msSBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-25.33", "spread": "13.942"}]}]}, {"title": "msDBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-12.40", "spread": "9.371"}]}]}]}, {"type": "SECONDARY", "title": "Percent of Responders for Mean Sitting Systolic Blood Pressure [msSBP] and for Mean Sitting Diastolic Blood Pressure [msDBP]", "description": "Response for mean sitting Systolic Blood Pressure \\[msSBP\\] is defined as a reduction of \u2265 20 mmHg from baseline or mean sitting Systolic Blood Pressure \\[msSBP\\] \\< 140 mmHg (non diabetics) or \\< 130 mmHg (diabetics). Response for mean sitting Diastolic Blood Pressure \\[msDBP\\] is defined as a reduction of \u226510 mmHg from baseline or mean sitting Diastolic Blood Pressure \\[msDBP\\] \\< 90 mmHg (non diabetic) or \\< 80 mmHg (diabetics).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "24 weeks", "groups": [{"id": "OG000", "title": "Aliskiren-based Regimen", "description": "Patients initiated treatment with aliskiren 150 mg (up-titrated to aliskiren 300 mg), followed by the addition of HCTZ 12.5 mg (up-titrated to 25 mg) and amlodipine 5 mg (up-titrated to 10 mg), as necessary to achieve the Blood Pressure goal."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "256"}]}], "classes": [{"title": "msSBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "96.80"}]}]}, {"title": "msDBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "97.78"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Aliskiren", "description": "Aliskiren treatment step", "seriousNumAffected": 3, "seriousNumAtRisk": 256, "otherNumAffected": 0, "otherNumAtRisk": 256}, {"id": "EG001", "title": "Aliskiren + HCTZ", "description": "Aliskiren and HCTZ treatment step", "seriousNumAffected": 0, "seriousNumAtRisk": 197, "otherNumAffected": 0, "otherNumAtRisk": 197}, {"id": "EG002", "title": "Aliskiren + HCTZ + Amlodipine", "description": "Aliskiren + HCTZ + Amlodipine treatment step", "seriousNumAffected": 0, "seriousNumAtRisk": 119, "otherNumAffected": 0, "otherNumAtRisk": 119}], "seriousEvents": [{"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 256}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 197}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 119}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 256}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 197}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 119}]}, {"term": "Renal neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 256}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 197}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 119}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 256}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 197}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 119}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000075222", "term": "Essential Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "asFound": "Essential Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000006852", "term": "Hydrochlorothiazide"}, {"id": "C000446481", "term": "Aliskiren"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}, {"id": "D000092502", "term": "Renin Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M9910", "name": "Hydrochlorothiazide", "asFound": "Prescription", "relevance": "HIGH"}, {"id": "M352589", "name": "Aliskiren", "asFound": "Distribution", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}, {"id": "M2932", "name": "Renin Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}